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Cardiovascular disease remains the bane of patients average peritoneal solute transport patterns by perito-
neal equilibration testing (PET) were most likely to ex-requiring renal replacement therapy. A major element
in this grave morbidity profile is the cumulative cardio- perience inadequate ultrafiltration (UF) [1].
The PD population has a high prevalence of hyperten-vascular burden incurred during the long history of
chronic kidney disease (CKD). A high proportion of sion as illustrated by data obtained from surveys of U.S.
[2] and Italian PD populations [3] (Fig. 2). Both studiesCKD patients present with cardiovascular disease at the
document a relatively high rate of elevated blood pres-time of dialysis initiation, notably left ventricular hyper-
sure (BP) among patients on PD as defined by the Sixthtrophy, coronary artery disease and congestive heart fail-
Joint National Committee on Hypertension (JNC6).ure (CHF). Data from the United States Renal Data
Moreover, little improvement in BP control was notedSurvey (USRDS) continue to show a high prevalence of
in the U.S. study over the three-year observation periodcongestive heart failure at the time of dialysis initiation
of 1995 to 1997, and there was no difference in the preva-in the U.S. end-stage renal disease (ESRD) population,
lence of hypertension between patients on CAPD orranging from 30 to 45% of patients depending on age
those using cycler therapy [2]. In the Italian study, poorgroup (Fig. 1). This prevalence has not changed since
control was observed despite widespread use of antihy-1995. A higher proportion of patients on hemodialysis
pertensive therapy [3]. Of particular concern was the(HD) have CHF at dialysis initiation and experience
absence of nocturnal BP dipping in over 50% of thehospitalizations due to CHF in the first year on dialysis
patients evaluated by ambulatory blood pressure moni-compared to peritoneal dialysis (PD) patients. Cardio-
toring [3].vascular disease in PD patients remains a concern requir-
ing therapeutic focus.
Relevance of enhanced fluid managementClinical observations continue to document subopti-
The importance of fluid management on patient out-mal fluid management across peritoneal dialysis popula-
come has been repeatedly demonstrated. A recent perti-tions. In a retrospective review, Tazamaloukas et al ob-
nent study by Ates et al evaluated the impact of fluid andserved a 25% incidence of symptomatic fluid retention
sodium removal on morbidity and mortality outcomesamong 262 patients treated predominantly with continu-
in PD [4]. One hundred and twenty five patients wereous ambulatory peritoneal dialysis (CAPD) patients
monitored for three years from the beginning of treat-(95%) [1]. Peripheral edema (100%), pulmonary conges-
ment. Both fluid and sodium removal were independenttion (80%), pleural effusions (76%), and systolic (83%)
predictors of death by univariate and multivariate analy-and diastolic (66%) hypertension were the most common
sis [4]. The survival rate—determined by Kaplan-Meiermanifestations of fluid retention [1]. The hospitalization
survival analysis—increased linearly with both fluid andrate for fluid retention was 4.1  5.8 days per patient
sodium removal. Elevated systolic blood pressure (SBP)per year, a rate significantly higher than that observed
also was associated with increased mortality. The signifi-for the total PD population. Patient noncompliance with
cant negative correlations between blood pressure (BP)dietary restrictions and with the prescribed PD prescrip-
and fluid and sodium removal underscores the clinicaltion was identified as the major predictor of fluid reten-
relevance of fluid management in PD [4].tion by logistic regression. Patients with high or high-
Moist and her colleagues have examined a variety of
factors relevant to the decline of residual renal function
(RRF) in patients on PD and HD [5]. In both groups a
history of congestive heart failure was a strong indepen- 2002 by the International Society of Nephrology
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Fig. 3. Success in control of hypertension in PD patient by strict fluidFig. 1. Prevalence of congestive heart failure (CHF) in patients initiat-
management is illustrated by the study of Gu¨nal et al [6]. The numbering dialysis in the United States of America in the years 1996, 1998,
of patients requiring antihypertensive medications for blood pressureand 2000 showing persistently high proportions. Symbols represent ages:
control was progressively reduced and those requiring oral antihyper-( ) 45 to 64; ( ) 65 to 74; () 75. The prevalence of CHF was age
tensives were controlled by a single agent.dependent. Data are from the 2001 USRDS Report.
without alteration in dialysis prescription. In patients
with persistent elevation of blood pressure, enhanced
peritoneal ultrafiltration was implemented by the use
of a hypertonic dialysis solution (4.25% dextrose). Salt
restriction alone or combined with UF led to a decline
in body weight by a mean of 2.8 kg, and BP decreased
from a mean of 158.2  17.0/95.7 10.3 to 119.7 16.0/
77.9  9.7 mm Hg in 37 patients. Cardiothoracic index
decreased in this group from 48.0  5.6% to 42.9 
4.5%. In seven patients who did not respond to the above
regimen, addition of an angiotensin converting enzyme
inhibitor reduced BP from 158.8  23.2/111.6  9.8 to
113.5 14.3/76.4 6.2 mm Hg. The cardiothoracic index
in these patients was 41.2%  1.3%, indicating the ab-
Fig. 2. Profile of blood pressure control in patients on peritoneal dial-
sence of hypervolemia [6]. In three patients the desiredysis in the United States of America and Italy classified by the criteria
of the Sixth Joint National Committee on Hypertension (JNC6). A results could not be reached because of noncompliance.
high prevalence of poorly controlled hypertension is clearly demon- The evolution of patient response is illustrated in Figure
strated. Data are from references [2, 3].
3. After four weeks on salt restriction alone, 20 patients
became normotensive with significant decreases in body
weight and cardiothoracic index. In the remaining hyper-
dent predictor of the decline in residual renal function tensive patients, the enhancement of ultrafiltration led
(adjusted odds ratio  1.32; P  0.03). In PD patients to normalization of blood pressure in a large proportion
alone, the adjusted odds ratio for an impact of the pres- [6]. These findings (Fig. 3) highlight the causative role of
ence of a history of congestive heart failure was 1.50 volume expansion in the etiology of hypertension among
(P  0.02) [5]. While these observations do not prove patients on CAPD given that 91% became normotensive
causality, it is reasonable to assume that the decline in with volume control alone.
residual renal function is accelerated in the presence of
Therapeutic limitationsdecompensated fluid overload state and that correction
of fluid overload and prevention of overt congestive Achieving fluid balance is a major goal of peritoneal
heart failure may retard the decline in residual renal dialysis and presents significant clinical challenges [7, 8].
function. The multifaceted nature of volume homeostasis and the
complexities involved in controlling influencing factors
Therapeutic success contribute to this challenge. Complicated dietary restric-
Gunal et al evaluated the impact of strict volume con- tions and patient compliance often hamper effective vol-
trol in 47 hypertensive patients on CAPD (Fig. 3) [6]. ume control [7, 8]. Similarly, the progressive loss of resid-
Antihypertensive medications were discontinued at the ual renal function and the development of diuretic
resistance further confound effective volume manage-beginning of the study and salt restriction was initiated
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Fig. 5. Prevalence of negative net ultrafiltration (drain volume less
than fill volume) in (A) CAPD and (B ) APD patients treated with
glucose based dialysate with various concentrations. Data are from
references [11, 13, 47].
Fig. 4. Differential effects of dwell time or drain volume on peritoneal
clearance of 2-microglobulin. Increasing dwell time from 12 to 24
hours and not drain volume (by increasing the number of exchanges
of 2 L each) was effective in increasing clearance. Data are from refer- not change when there was an increase in the number
ence [10]. of dialysate exchanges from 2 to 3 and from 3 to 4 over
a period of 24 hours; whereas the peritoneal clearance
of creatinine increased. In contrast to peritoneal clear-
ment [9]. Medcalf, Harris and Walls have profiled the ance of small molecules, such as creatinine, which was
course of urinary output and sodium excretion in new dependent on the number of dialysate exchanges, perito-
patients starting PD [9]. Over the course of one year neal clearance of middle molecules such as 2-micro-
urinary output and urinary sodium excretion declined by globulin depended mainly on the total dwell hours of
30% [9]. While both urine output and sodium excretion PD and not on the number of exchanges [10].
could be enhanced by administration of large doses of The long dwell has significant limitations from the
furosemide, the response to the loop diuretic declined standpoint of fluid removal [7, 8]. Negative net ultrafil-
with time. Response to diuretics is negligible in patients tration during the long dwell is a measure of therapeutic
who have a spontaneous urine output less that 100 mL, failure of fluid control. Negative net UF is defined as a
and most patients have minimal residual renal function drain volume that is lower than instilled volume. In an-
after 36 months of dialysis therapy [9]. Notably, the use uric patients a neutral net ultrafiltration (drain volume
of diuretics while maintaining urinary water and sodium equals instilled volume) represents a lost therapeutic
excretion had no effect on the course of urea and creati- opportunity. The prevalence of negative net UF has been
nine clearances that declined over time [9]. documented in several studies (Fig. 5). In the MIDAS
An additional factor limiting therapeutic success in
study [11, 12], negative net UF was observed in a largePD is the profile of ultrafiltration during the long dwell
number of CAPD patients using 1.5% dextrose solutionswith dextrose-based dialysis solutions [7, 8]. The long
for the long dwell (Fig. 5). This proportion was exagger-dwell is both a logistic and a clinical requirement to
ated when the long dwell was extended from 8 to 12maintain a continuously wet abdomen and lower the
hours. A lower proportion of patients experienced nega-logistic burden on patients. Long dwell exchanges con-
tive net UF when 4.25% dextrose solutions were used,tribute to small solute clearance and are critical for the
but the proportion remained sensitive to dwell duration.removal of middle and large molecular weight (MW)
The profile of negative net UF with 2.5% dextrose intoxins, a process that is more time- than flow-dependent.
CAPD patients was recently described by Wolfson et al,In addition, the long dwell offers patients a lifestyle
where 20% of CAPD patients displayed negative netfriendly therapeutic option, thereby enhancing compli-
UF when using 2.5% dextrose for the long dwell, andance and quality of life.
the effect was more pronounced among patients withThe time dependence of middle molecule clearance
high and high-average transport profiles (abstract; J Amhas been studied recently by Kim et al, who evaluated
Soc Nephrol 12:317A, 2001).the impact of peritoneal dialysis schedule on middle (2-
In automated peritoneal dialysis (APD) patients, themicroglobulin) and small molecule (creatinine) perito-
prevalence of negative net UF is exaggerated becauseneal clearance in 111 patients [10]. Peritoneal clearance
of the longer dwell times employed during the day dwell.of creatinine increased with the increase in the number
Plum et al have described the persistent high prevalenceof daily exchanges. In contrast, clearance of 2-micro-
of negative net UF in this population (Fig. 5) with theglobulin nearly doubled with an increase in dwell time
(Fig. 4). Peritoneal clearance of 2-microglobulin did use of 2.5% dextrose for the long dwell [13]. Similar
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pressure with limited requirements for antihyper-
tensive agents [6].
(4.) Peripheral edema indicates a clear state of fluid
overload of several liters [31, 32], and an edema
free state is a minimal requirement for normovo-
lemia.
(5.) An edema free state, however, does not ensure
normovolemia, as several liters of excess fluid are
required before edema becomes clinically detect-
able [31, 32].
(6.) Fluid overload in PD patients is a strong predictor
of poor outcomes [4].
It is always necessary to temper therapeutic recom-
mendations with clinical experience. Despite significant
advances in the management of orthostatic hypotension
associated with autonomic insufficiency, a degree of vol-
ume expansion is frequently required in clinical practice
to help support blood pressure levels compatible with
upright posture [33–37]. An additional condition requir-
ing allowance of some degree of edema is in patients
Fig. 6. Algorithm for fluid management in patients on PD. Therapeutic with cardiomyopathy in whom a significant reduction in
goals. filling pressure with volume contraction may result in
symptomatic hypotension.
Control of blood pressure predominantly by correc-
tion of volume rather than reliance on antihypertensivefindings were reported by Woodrow and colleagues, who
agents does not require discontinuation of such agentsalso showed the tonicity dependence of this phenomenon
that are being used for renoprotective and cardioprotec-[14]. In their study, a negative net daytime UF was noted
tive indications distinct from blood pressure control. Thein 14 of 17 (82%) patients with 2.5% dextrose, and in 4
use of angiotensin converting enzyme (ACE) inhibitorsof 17 (24%) patients with 4.25% dextrose [14].
in patients on dialysis has been associated with better
preservation of residual renal function, and hence their
use for that purpose is not excluded by the present algo-ALGORITHM OVERVIEW
rithm [5]. Similarly, if beta-blockers are used for eitherDefining therapeutic goals
primary or secondary prevention of ischemic heart dis-
In recommending the adoption of a clinical algorithm, ease [38–42] or management of congestive heart failure
several principles are required for purposes of clarity [43–46], their use need not be questioned. If a decision
and relevance [15–24], including a clear definition of is made to maintain the use of these agents, then the
therapeutic goals, interventional maneuvers, and diag- effort to achieve normovolemia and normotension needs
nostic endeavors. The therapeutic goal is the anchor of to be balanced by their continued use.
an interventional algorithm, and needs to be supported
by evidence, be consonant with clinical wisdom and expe- Pathway analysis
rience, and flexible enough to accommodate variant con- The algorithm depicted in Figures 6 to 8 codifies a
ditions. The therapeutic goals for the present algorithm systematic approach to the achievement of the stated
are twofold: all PD patients need to be edema free and therapeutic goals. The presence or absence of edema is
an effort should be made to achieve normotension with the primary step. If edema is absent, then blood pressure
minimal use of or need for antihypertensive medications control and the degree of dependence on antihyperten-
(Fig. 6). Supporting evidence consists of the following: sive agents is examined. If in either of these two steps
there is deviation from therapeutic goal, a series of inter-
(1.) Blood pressure control in PD patients remains ventions is recommended (Table 1).
suboptimal [2, 3]. When evaluating dialytic fluid removal, it is clinically
(2.) Hypertension in patients with ESRD is predomi- useful to look first at the long dwell (Fig. 7), as this
nantly volume dependent (salt sensitive) [25–30]. component of the prescription is the most frequent cause
(3.) Correction of volume expansion in ESRD pa- of therapeutic failure in volume removal [8, 14, 47–49].
If negative ultrafiltration is observed during the longtients is associated with normalization of blood
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Table 1. Areas of intervention in case of fluid overload
Dietary evaluation
Salt intake
Fluid intake
Residual renal function
Temporal trends in urine volume
Use of diuretics
Profile of decline in glomerular filtration rate
Medications effects
Use of ACE inhibitors to preserve RRF
Compliance
Quality of life issues
Inventory control
Delivered dose
Edema characterization
Localized vs. generalized
Temporal trends in severity
Catheter function
Outflow obstruction
Leaks and hernias
Peritoneal UF profile
Fig. 8. Algorithm for fluid management in patients on PD. Manage-
ment of the short dwell.
clearances (urea and creatinine) needs to be revisited in
light of recent studies [51].
When the clinician is satisfied that the UF achieved
during the long dwell is satisfactory, the need for further
enhancement of peritoneal ultrafiltration requires exam-
ination of the short dwell components of the therapy
(Fig. 8) [8].
DETAILS OF THE ALGORITHM COMPONENTS
Evaluation of long dwell UF
The long dwell should be the first component of the
therapy subjected to scrutiny given the significant limita-
tions encountered with the use of low tonicity glucose-
based dialysis solutions (Fig. 5). Inadequate ultrafiltra-Fig. 7. Algorithm for fluid management in patients on PD. Therapeutic
goals and management of the long dwell. tion during the long dwell is a lost therapeutic opportu-
nity that can overburden the other components of the
therapy. Interventions during the long dwell include: use
of very hypertonic glucose-based solutions now recog-dwell, then a series of interventions needs to be consid-
nized as a potential source of peritoneal membrane dam-ered, as described later in this article. A neutral or low
age [50]; reduction in the length of the dwell by use ofnet ultrafiltration may be considered a lost therapeutic
a nighttime exchange device in CAPD, or the use of aopportunity in patients deviating from the therapeutic
midday exchange in APD (the impact of the latter needsgoals, and may be used as an indication for further inter-
to be evaluated in terms of quality of life cost) [8]. Theventions. If the net ultrafiltration during the long dwell
availability of icodextrin-based solutions has greatly sim-is quantitatively adequate, the qualitative cost of utiliza-
plified the task of assuring positive net ultrafiltrationtion of very hypertonic glucose solutions (4.25% dex-
during the long dwell [abstracts; Douma et al, J Am Soctrose) needs to be considered to limit the nefarious con-
Nephrol 8:282A, 1997; Van Bree et al, Perit Dial Intsequences of the use of 4.25% dextrose [50]. The practice
of using 4.25% dextrose solutions to increase small solute 20(Suppl 1):S14, 2000] [14, 47, 52–56].
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tonicities for the various bags. The most common glucose
concentrations used are 1.5%, 2% and 2.5%. The 2%
is the result of equal mixing of bags of the other two
concentrations. It is more efficient to increase UF by
choosing higher tonicities than by increasing cycle number
(Fig. 13). A concern frequently voiced regarding increas-
ing tonicity is the caloric cost of higher glucose concentra-
tions. For ultrafiltration using a cycler, the caloric cost per
milliliter of ultrafiltration can be estimated from computer
modeling [57–60]. If examined from the standpoint of
caloric cost per milliliter of ultrafiltration achieved, the
cost is actually lower with the use of higher tonicities (Fig.
14). Expressed differently, the ultrafiltration advantage of
Fig. 9. Relationship between cycle number and cycle duration during
the higher tonicity exceeds the caloric cost.the nighttime phase of APD. With increasing cycle number, the duration
of a dwell is shortened. This effect is due to the proportional require- Impact of fill volume. Early experience with perito-
ments for fill and drain. The curves illustrate the changes in cycle neal dialysis in children had suggested that a small fill
duration by differing therapy times.
volume is associated with decreased ultrafiltration. The
mechanism underlying this clinical observation has been
elucidated in experimental studies by Wang et al showingOptimization of short dwell UF
that increasing fill volume is associated with increased
Automated peritoneal dialysis creates a biphasic pro- ultrafiltration ascribed to the preserved glucose gradient
file for ultrafiltration behavior by intensifying therapy because of higher glucose total mass in the peritoneal
delivery during the nighttime hours [8]. The nighttime cavity consequent to the higher fill volume [61, 62]. Clini-
phase is characterized by short dwell times and numerous cal validation of this finding comes from single dwell
cycles with new dialysate. Dissipation of dialysate/plasma studies in patients on PD [63]. Concerns have been
glucose gradient is non-linear with a rapid initial decline raised, however, regarding the impact of increased fill
followed by a slow decrement. This implies that the glu- volume on intraperitoneal pressure (IPP) and the effect
cose gradient driven ultrafiltration rate is non-linear and of the latter on fluid reabsorption. Increases in dwell
maximal during the early part of the dwell. While shorter volumes from 2 L to 3 L result in a rise in intraperitoneal
cycles appear theoretically favorable to ultrafiltration pressure of 2 cm H2O. As dwell times in APD are short,
because of maintenance of optimal conditions for fluid the effect is expected to be modest. Higher fill volumes
removal, the frequency also introduces an “inactive time” are usually utilized in individuals with larger body habi-
because of the requirements for drainage and fills. Figure tus and it is reasonable to expect more modest increment
9 illustrates the dwell duration with an increasing number in IPP when fill volume is increased in large size individu-
of cycles during 7 to 9 hour treatments. With increasing als. Clinically, an increase in fill volume is used to in-
cycle number, cumulative drain-fill time rises and the crease total dialysate volume to achieve better clearance
dwell time per cycle shortens. Theoretically, this would and is not associated with a change in cycle number or
be expected to enhance ultrafiltration as the system is duration. In such a setting, maintenance of the glucose
operating on the steeper part of the osmotic dissipation gradient and an increase in UF are expected [63]. Propor-
curve (Fig. 10). The effect is quite modest likely because tionally more glucose remains in the peritoneal cavity
of the diminishing “active” treatment time and the higher with higher fills and hence the end of dwell tonicity is
proportion of drain-fill time to total therapy time (Fig. expected to be higher with the higher fill volume.
11). Since what matters clinically is cumulative ultrafil-
Residual renal functiontration and not ultrafiltration rate, the shortening of dwell
time will result in lower ultrafiltration after a certain num- Monitoring of trends in urine volume should be part
ber of cycles is reached (Figs. 11 and 12). The role of of the standard care of patients on peritoneal dialysis.
“inactive time” for both clearance and ultrafiltration The largest change in urine output is usually observed
needs to be considered in prescription regimens in adult in the first month of therapy as PD corrects the polyuria
patients that exceed 5 cycles during an 8 to 9 hour cycler of chronic kidney disease by reducing the osmotic load
time. and extracellular volume expansion. Subsequent changes
Impact of tonicity. A unique aspect of APD that dif- in urine output are usually slowly progressive except in
ferentiates it from CAPD is the ability to titrate the the setting of peritonitis, acute illnesses, and the use of
tonicity required [8]. Because solutions from dialysate nephrotoxic agents (aminoglycosides, non-steroidal anti-
bags are proportionally mixed by the cycler, the tonicity inflammatory drugs, contrast agents, etc.) when abrupt
changes in urine output may occur. If peritoneal ultrafil-of the dialysate can be titrated by choosing different
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Fig. 10. Correspondence between dwell time
with different cycle number (A) and the corre-
sponding decline in osmotic gradient (B ) as
illustrated by the changes in dialysate glucose
concentration ratio (D) compared to baseline
glucose (D0). The four peritoneal transport
types are represented by the different areas
in the right hand panel: Low transport (L),
low average transport (LA), high average
transport (HA), and high transport (H).
Fig. 13. Nighttime ultrafiltration in APD increases with increasing to-Fig. 11. Nighttime ultrafiltration in patients on APD with variations
nicity. Symbols are: () 1.50%; () 2.00%; () 2.50%. It is morein number of cycles. Increasing cycle number beyond 5 is associated
efficacious to increase UF by increasing tonicity than by increasingwith diminishing net UF because of the disproportional increase in
cycle number. Curves for a high average (HA) transport patient arerelative “no therapy time” during fill/drain periods. Profiles for patients
illustrated.with high average (HA) and low average (LA) transport are illustrated.
Fig. 12. Net ultrafiltration per cycle declines with increasing cycle num-
ber because of the reduced time for ultrafiltration. Although shorter Fig. 14. Caloric gain per milliliter of ultrafiltration. Symbols are: ()
1.50%; () 2.50%. Fewer calories from glucose are gained per mL ofcycles operate at higher ultrafiltration rates, the cumulative ultrafiltra-
tion tends to be lower. net ultrafiltration with the use of higher tonicity solutions.
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tration is not adjusted to compensate for the reduction fluid management. Studies of inventory control to date
have focused on volumes of solution used. The type ofin urine output, fluid overload will occur. Measuring
urine volume allows for interventions if abrupt changes solutions used (tonicity, osmotic agent etc.) may be the
next level of detail that future studies of compliance mayare observed, and facilitates monitoring of diuretic re-
sponsiveness. need to address. In Mexico where only two tonicities of
dialysis solutions have been available (1.5% and 4.25%
Compliance dextrose), a very low level of 4.25% utilization has been
Non-compliance may alter fluid balance by affecting associated with increased prevalence of fluid overload
dietary sodium and water intake, adherence to diuretic and congestive heart failure (Alfonso Ramos, M.D., per-
regimens, and changes in peritoneal dialysis prescription. sonal communication).
The general assumption that patients on peritoneal dial- In summary, we recommend that all PD patients need
ysis tolerate greater dietary salt and fluid indiscretion to be edema free and an effort should be made to achieve
should not be construed as an endorsement for such normotension with minimal use of or need for antihyper-
indiscretion [7, 8]. It is recognized that dietary interven- tensive medications. This therapeutic goal can be achieved
tions are the hardest to implement as they involve an by following the practical algorithm delineated in this
elaborate process of education and lifestyle modification. article.
The role of therapy adherence in an evaluation of fluid
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in small solute clearance. Evaluation of adherence with Park, Illinois 60085-9815.
E-mail: mujaiss@baxter.comtherapy has shown a close correlation with patient out-
comes and therapy technique failure [64, 65]. Survey
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